TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
30 nov. 2023 08h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023
27 nov. 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
Company remains on track to report initial data from TFF VORI and TFF TAC Phase 2 trials by the end of 2023 Conference call and webcast, today Tuesday November 14, 2023, at 4:30 pm ET to provide...
TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing
08 nov. 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023
07 nov. 2023 16h05 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 07, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines
02 oct. 2023 17h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in Upcoming Investor Conferences
28 sept. 2023 16h29 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
23 août 2023 07h00 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
17 août 2023 16h01 HE
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Aug. 17, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
15 août 2023 06h05 HE
|
TFF Pharmaceuticals, Inc.
Announced pricing of approximately $5 million equity financing (approximately $5.7 million if underwriter’s overallotment option is exercised in full); expected to extend cash runway through initial...